SpyGlass Pharma, Inc.
No SEC Form 4 filings for $SGP in the last 30 days.
See all $SGP insider activity →HC Wainwright & Co. maintained a Buy rating on SpyGlass Pharma with a $37 price target, implying 48.5% upside. The company's BIM-IOL System is in Phase 3 trials, and its acquisition of Advanced Vision Science enhances manufacturing capabilities. The stock closed at $24.92 on Oct 2.
Stifel maintained a Buy rating and $42.00 price target for SpyGlass Pharma (SGP) after its $13M acquisition of Advanced Vision Science. SGP trades at $26.50, with targets ranging from $37 to $62. The deal secures manufacturing capacity for SGP's BIM-IOL System. SGP expects sufficient cash runway through 2028 and has a current ratio of 25.06. Raymond James initiated coverage with an Outperform rating and $39.00 target.
SpyGlass Pharma (SGP) acquired Advanced Vision Science (AVS) for $13M, securing IOL manufacturing capacity for its BIM-IOL System. AVS will continue supplying IOLs to Santen, Bausch + Lomb, and others. The deal aims to accelerate SpyGlass's lens portfolio expansion and support its Phase 3 trials.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SGP (SpyGlass Pharma, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SGP coverage spans financial news, mergers & acquisitions and technology.
HC Wainwright & Co. maintained a Buy rating on SpyGlass Pharma with a $37 price target, implying 48.5% upside. The company's BIM-IOL System is in Phase 3 trials, and its acquisition of Advanced Vision Science enhances manufacturing capabilities. The stock closed at $24.92 on Oct 2.
The acquisition strengthens SpyGlass's supply chain and may boost investor confidence.
The deal removes supply risk and adds manufacturing capability, likely supporting the stock.
Positive trial progression may lift valuation as the company de-risks its lead product and approaches regulatory filing.
The expansion and regulatory code approval reduce execution risk and may support near‑term price appreciation.
AlphAI scores every news story that mentions SGP with an AI model for sentiment and relevance, and aggregates insider trades from SpyGlass Pharma, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
HC Wainwright & Co. maintained a Buy rating on SpyGlass Pharma with a $37 price target, implying 48.5% upside. The company's BIM-IOL System is in Phase 3 trials, and its acquisition of Advanced Vision Science enhances manufacturing capabilities. The stock closed at $24.92 on Oct 2.
1 min readStifel maintained a Buy rating and $42.00 price target for SpyGlass Pharma (SGP) after its $13M acquisition of Advanced Vision Science. SGP trades at $26.50, with targets ranging from $37 to $62. The deal secures manufacturing capacity for SGP's BIM-IOL System. SGP expects sufficient cash runway through 2028 and has a current ratio of 25.06. Raymond James initiated coverage with an Outperform rating and $39.00 target.
2 min readSpyGlass Pharma (SGP) acquired Advanced Vision Science (AVS) for $13M, securing IOL manufacturing capacity for its BIM-IOL System. AVS will continue supplying IOLs to Santen, Bausch + Lomb, and others. The deal aims to accelerate SpyGlass's lens portfolio expansion and support its Phase 3 trials.
2 min readSpyGlass Pharma (SGP) presented at Citigroup’s Biopharma Summit, outlining plans for its BIM-IOL drug-device platform. The company reported strong clinical data, with 95% of patients free of additional glaucoma therapy at three years in early trials. SpyGlass has $234 million in cash, expects Phase III trial completion in 2028, and aims for a 2029 launch. The company targets a market of 200,000 annual cataract procedures in the U.S. with glaucoma.
3 min readSpyGlass Pharma Inc. (Nasdaq: SGP) has moved to a larger headquarters in Irvine, accommodating up to 150 employees. The biopharmaceutical company, which went public in February, is focused on drug delivery solutions for chronic eye conditions. It is currently conducting Phase 3 trials for its lead product, the BIM-IOL system, with a target launch in 2029. The company's stock traded at $28.99 with a $970 million market cap, up 77% since its IPO. SpyGlass has also secured a new AMA Category III co
3 min readThe article reports Friday’s Wall Street analyst research calls after cooler-than-expected CPI and PPI helped lift the S&P 500 to a record and Nasdaq up 0.81%. It cites upgrades, downgrades, and initiations including JPMorgan upgrading FoxA to Overweight with an $82 target and RBC initiating Krystal Biotech (KRYS) at $400. It also lists multiple other price targets across stocks.
3 min readSpyGlass Pharma, Inc. (SGP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SpyGlass Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027. •
6 min readManila Electric Co. (Meralco) said it will join discussions on proposed amendments to the Electric Power Industry Reform Act (EPIRA) that could remove system loss charges from electricity bills. Meralco warned reforms should preserve distribution utility investment capacity. System loss is about 5% of bills in Meralco’s area. Meralco shares fell 4.66% to P562; SGP fell 0.36% to P28.
4 min readAustralia’s ASX 200 (XJO) closed at 8,947.8, up 0.61%, a six-week high, after RBA Governor Michele Bullock signaled housing and labour markets have softened more than expected, easing August rate hike fears. The 10-year yield fell 5.2 bps. Consumer, tech and financials rose; gold, copper and lithium stocks fell.
7 min readSpyGlass Pharma Inc. appointed Shannon Treviño as general counsel, the company said. Treviño previously served as general counsel and corporate secretary at Inari Medical, acquired by Stryker for $4.9 billion, and held earlier legal and academic roles. SpyGlass CEO Patrick Mooney said she will support the company’s growth. Shares rose 2.7% to $18.93.
2 min read
